MANNKIND CORP business relationships
Companies named in MANNKIND CORP’s 10-K filed 2026-02-26, and public companies whose annual reports name MANNKIND CORP. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.4 / 10
- AI naming
- 72 / 100 Top 1% in its category
- Agent readiness
- 25 / 100
- AI adoption
- 0 / 100
Named in MANNKIND CORP’s annual report 8
“The infusor is made by West Pharmaceutical Services, Inc. ("West") pursuant to a supply agreement that currently extends through December 31, 2027 (as” SEC filing
“Cipla License and Distribution Agreement - In May 2018 , the Company and Cipla Ltd. ("Cipla") entered into an exclusive agreement for the marketing and distribution of Afrezza in India and the Company received a $ 2.2 million nonrefundable license fee.” SEC filing
“In December 2025, we supplied our partner in India, Cipla Ltd. ("Cipla"), with an initial shipment of Afrezza to support their launch of Afrezza in India.” SEC filing
“Concurrently, the Company and Pulmatrix entered into a cross-license agreement (the "Cross License Agreement") and a master service agreement.” SEC filing
“United Therapeutics License Agreement - In September 2018, the Company and UT entered into an exclusive global license and collaboration agreement (the "UT License Agreement"), pursuant to which UT is responsible for global development, regulatory and commercial activities with respect to Tyvaso DPI...” SEC filing
“Our development and marketing partner (sometimes referred to as our collaboration partner), United Therapeutics Corporation ("United Therapeutics" or "UT") began commercializing Tyvaso DPI in June 2022 and is obligated to pay us a royalty on net sales of the product.” SEC filing
“Cost of goods sold excludes the cost of insulin purchased under the Company's Insulin Supply Agreement (the "Insulin Supply Agreement") with Amphastar Pharmaceuticals, Inc. ("Amphastar").” SEC filing
“Because United Therapeutics is solely responsible for the development, marketing, promotion, and sale of Tyvaso DPI, our ability to maintain and grow this revenue is highly dependent on the commercial performance of Tyvaso DPI and on United Therapeutics' strategic priorities, resource allocation dec...” SEC filing
Companies whose annual reports name MANNKIND CORP 6
“pursuant to the Cross License Agreement, MannKind granted to the Company (i) the exclusive right to develop, use, manufacture, market,” SEC filing
“The increase in selling, distribution and marketing expenses was primarily due to expenses related to the expansion of our sales and marketing efforts related to BAQSIMI ® , including expenses related to our co-promotion contract with MannKind, and sales efforts related to Primatene MIST ® .” SEC filing
“We have amended our supply agreement with MannKind, or the Supply Agreement and our option purchase agreement with MannKind, or the Option Agreement, multiple times to modify and extend the annual minimum purchase commitments under the Supply Agreement and the Option Agreement.” SEC filing
“We pay a ten percent royalty on our net sales of Tyvaso DPI under our license agreement with MannKind.” SEC filing
“First Amendment to License and Collaboration Agreement, dated August 24, 2025 between the Registrant and MannKind Corporation, incorporated by reference to Exhibit 10.” SEC filing
“Pursuant to the Supply Agreement, MannKind is responsible for manufacturing and supplying Tyvaso DPI to us.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.